Cargando…
Infliximab in the treatment of plaque type psoriasis
Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Inf...
Autores principales: | Saraceno, Rosita, Saggini, Andrea, Pietroleonardo, Lucia, Chimenti, Sergio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047936/ https://www.ncbi.nlm.nih.gov/pubmed/21436966 |
Ejemplares similares
-
Infliximab for the treatment of plaque psoriasis
por: Gall, Jennifer S, et al.
Publicado: (2008) -
IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants
por: Saggini, Andrea, et al.
Publicado: (2014) -
Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
por: Saraceno, Rosita, et al.
Publicado: (2013) -
Profile of certolizumab and its potential in the treatment of psoriatic arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2013) -
Treatment of severe psoriasis with infliximab
por: Leman, JA, et al.
Publicado: (2008)